Vyvanse is a medicine containing the active ingredient(s) lisdexamfetamine. On this page you will find out more about Vyvanse, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: lisdexamfetamine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Vyvanse 20 mg hard capsule, 30
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Attention Deficit Hyperactivity Disorder (ADHD): VYVANSE is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment should be commenced by a specialist. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before 12 years of age.,Need for comprehensive treatment programme: VYVANSE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational and social) for patients with this syndrome. Stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physicians assessment of the chronicity and severity of the patients symptoms.,Long term use: The physician who elects to use VYVANSE for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.,Binge Eating Disorder (BED): VYVANSE is indicated for the treatment of moderate to severe BED in adults when nonpharmacological treatment is unsuccessful or unavailable. Treatment should be commenced and managed by a psychiatrist.,Need for comprehensive treatment programme: VYVANSE is indicated as part of a total treatment program for BED that optimally includes other measures (nutritional, psychological, and medical) for patients with this disorder. When remedial measures including psychotherapy are insufficient, the decision to prescribe stimulant medication will depend upon the physicians assessment of the chronicity and severity of the patients symptoms.,Limitation of Use: VYVANSE is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of VYVANSE for the treatment of obesity have not been established. Prescribers should consider that serious cardiovascular events have been reported with this class of sympathomimetic drugs. The BED clinical trials were not designed to assess cardiovascular safety. While there is an accumulation of safety data with VYVANSE use in the ADHD population, this is of limited relevance regarding cardiovascular risk in the BED population. Given the higher cardiovascular risk associated with obesity, the BED population may be at a higher risk. See Sections 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE, Cardiovascular Disease and 4.2 DOSE AND METHOD OF ADMINISTRATION.,Long term use: For BED the initial treatment period is 12 weeks. Patients should then be observed to assess whether further treatment with VYVANSE is required. Periodic re-evaluation of the usefulness of VYVANSE for the individual patient should be undertaken. See Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials.
Table of characteristics
|Visual appearance||VYVANSE 20 mg capsule: ivory opaque body and ivory opaque cap, printed 'S489' and '20 mg' in black ink|
|Dosage Form||Capsule, hard|
|Route of administration||Oral|
30: Controlled Drug
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 2 results
Vyvanse Capsules - myDr.com.au
Vyvanse Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Stimulant medicines stimulate the central nervous system (CNS) by increasing the activity of certain chemicals in the brain. Dexamphetamine and methylphenidate are both stimulants.
Read more on WA Health website
Found 1 results
Attention Deficit Hyperactivity Disorder (ADHD) | Australian Sports Anti-doping Authority - ASADA
ADHD is one of the most common childhood disorders and can continue through adolescence and adulthood. Inattention, hyperactivity, and impulsivity are the key features of ADHD. Medical management of ADHD will include behavioural therapy and in many cases medication.Status of medication in sportStimulant medications, such as Methylphenidate (e.g. Ritalin, Concerta) and Dexamphetamine (e.g. Vyvanse, lisdexamphetamine) are prohibited in-competition and require a Therapeutic Use Exemption (TUE).
Read more on Australian Sports Anti-Doping Authority (ASADA) website